

Barcelona, February 9th 2016

## **SIGNIFICANT EVENT**

# **Almirall closes the acquisition of ThermiGen LLC entering the aesthetics market**

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces:

A definitive agreement to acquire 100% of the share capital of ThermiGen LLC, after all closing conditions have been satisfied. In accordance with the terms of the agreement, the transaction has been fulfilled and Almirall now owns this privately held medical aesthetics company, which is a leading developer of thermistor-regulated energy systems for Aesthetics Dermatology and Plastic Surgery applications.

Under the terms of the agreement, Almirall has acquired ThermiGen for an Enterprise Value of USD \$82 million. This acquisition represents the definitive entry of Almirall into the aesthetics market, an industry with potential global sales in high growth dermatological indications. The addition of ThermiGen's portfolio provides Almirall with a solid technology and commercial platform in the energy-based devices segment; a recurrent business model and an experienced management team with a proven track record. In 2014, ThermiGen had USD \$11.4 million of revenue and has already closed 2015 with nearly USD \$30 million in sales and positive operating results.

Almirall announced the exercise of a call option on January 4th 2016. Previously, in September 2015, Almirall acquired a minority stake in ThermiGen for USD \$5 million representing 7.7% of the share capital of the company and paid USD \$2.5 million in exchange of a call option right to acquire up to 100% of the company, now completed.

*ThermiGen's product portfolio is based on the 'Science of Heat', using SmartTip technology to enable physicians to use temperature as an endpoint to treat a variety of aesthetic soft tissue and nerve conditions. This technology is used for multiple non-invasive and minimally-invasive procedures, and it offers significant potential for multiple indications.*

*ThermiRF®, the company's flagship product, is the first FDA's cleared aesthetic device that employs temperature-controlled radio frequency to be used in dermatological and general surgical procedures for electrocoagulation and hemostasis; and to create lesions in nerve tissue. ThermiGen also has the worldwide rights to commercialize ThermiSmooth® 250, performed using a specially designed thermistor's regulated hand piece, which delivers precise heating to the skin's surface.*

Yours sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[inversores@almirall.com](mailto:inversores@almirall.com)